Immunic Current Valuation vs. Total Debt
| IMUX Stock | USD 1.18 0.09 7.09% |
For Immunic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunic utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunic over time as well as its relative position and ranking within its peers.
Immunic |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immunic Total Debt vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immunic's current stock value. Our valuation model uses many indicators to compare Immunic value to that of its competitors to determine the firm's financial worth. Immunic is rated below average in current valuation category among related companies. It is rated below average in total debt category among related companies making up about 0.02 of Total Debt per Current Valuation. The ratio of Current Valuation to Total Debt for Immunic is roughly 51.63 . Total Debt To Capitalization is likely to rise to 0.05 in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunic by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunic's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunic's earnings, one of the primary drivers of an investment's value.Immunic Current Valuation vs. Competition
Immunic is rated below average in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 4.07 Billion. Immunic claims roughly 68.87 Million in current valuation contributing just under 2% to equities under Health Care industry.
Immunic Total Debt vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Immunic |
| = | 68.87 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Immunic |
| = | 1.33 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Immunic Total Debt vs Competition
Immunic is rated below average in total debt category among related companies. Total debt of Health Care industry is currently estimated at about 510 Million. Immunic adds roughly 1.33 Million in total debt claiming only tiny portion of equities under Health Care industry.
Immunic Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immunic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunic will eventually generate negative long term returns. The profitability progress is the general direction of Immunic's change in net profit over the period of time. It can combine multiple indicators of Immunic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 3.8 M | 3.9 M | |
| Operating Income | -99.2 M | -94.3 M | |
| Income Before Tax | -93.6 M | -88.9 M | |
| Total Other Income Expense Net | 5.6 M | 5.9 M | |
| Net Loss | -93.6 M | -88.9 M | |
| Income Tax Expense | 39 M | 40.9 M | |
| Net Loss | -93.6 M | -98.3 M | |
| Non Operating Income Net Other | -827.1 K | -785.7 K | |
| Net Loss | -108.4 M | -102.9 M | |
| Interest Income | 3.1 M | 3.2 M | |
| Net Interest Income | 3.1 M | 3.2 M | |
| Change To Netincome | 52.5 M | 55.1 M | |
| Net Loss | (2.11) | (2.22) | |
| Income Quality | 0.76 | 1.02 | |
| Net Income Per E B T | 1.15 | 0.86 |
Immunic Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immunic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunic's important profitability drivers and their relationship over time.
Use Immunic in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunic will appreciate offsetting losses from the drop in the long position's value.Immunic Pair Trading
Immunic Pair Trading Analysis
The ability to find closely correlated positions to Immunic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunic to buy it.
The correlation of Immunic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Immunic position
In addition to having Immunic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Market Neutral Funds Thematic Idea Now
Market Neutral Funds
Funds or Etfs that invest in both long and short positions of different entities to enhance returns from broad market movements over time. The Market Neutral Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Market Neutral Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
To fully project Immunic's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immunic at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immunic's income statement, its balance sheet, and the statement of cash flows.